An intravenous insulin protocol for strict glycemic control in acute ischaemic stroke

被引:22
|
作者
Ntaios, G. [1 ]
Egli, M. [2 ,3 ]
Arsovska, A. [1 ]
Joye, D. [1 ]
Bettex, Y. [1 ]
Lauber, E. [1 ]
Eskandari, A. [1 ]
D'Ambrogio, S. [1 ]
Richoz, B. [1 ]
Ruiz, J. [2 ,3 ]
Michel, P. [1 ]
机构
[1] CHU Vaudois, Neurol Serv, CH-1011 Lausanne, Switzerland
[2] CHU Vaudois, Serv Endocrinol Diabet & Metab, CH-1011 Lausanne, Switzerland
[3] Univ Lausanne, Lausanne, Switzerland
关键词
intravenous insulin; ischaemic stroke; post-stroke hyperglycemia; POSTSTROKE HYPERGLYCEMIA; GLUCOSE-INSULIN; THERAPY; MANAGEMENT; INTERVENTION; ASSOCIATION; SAFETY; TRIAL;
D O I
10.1111/j.1468-1331.2011.03537.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: There is a J-shaped association between admission glycemia and outcome. We designed an intravenous insulin protocol aiming at rapid and strict glucose control in hyperglycemic ischaemic stroke patients. Here, we describe the initial experience, safety, and efficacy of this protocol to achieve and maintain euglycemia in the first 48 h. Methods: The protocol is based on parallel scales for adjustment of insulin infusion rate according to current glycemia and the rate of change of glycemia, which was recommended in our stroke unit in 4/2007 in acute ischaemic stroke patients with glycemia > 6 mM. Data were registered in the Acute Stroke Registry and Analysis of Lausanne (ASTRAL). Capillary blood glycemia was measured hourly with fingerprick test at onset of treatment and after each scale change. Target glycemia was 4.06.0 mM pre-prandially (5.5-8.0 mM post-prandially). Hypokalemia was defined as serum potassium < 3.5 mM and measured every 12 h. Specific algorithms were employed during meals and for patients leaving temporarily the stroke unit for diagnostic or therapeutic workup. Results: In the 90 protocol patients, the first normoglycemia was achieved within 8 h of treatment in 91.1% of patients (median interval 4 h (interquartile range (IQR): 3-6). During the median treatment duration of 25.5 h (IQR: 19.7-37.7), median glucose reduction was 2.5 mM (IQR: 1.3-4.3 mM). The overall rate of hypoglycemias was 4.5% and hypokalemias 18.5%. There was a significant increase in the proportion of hypokalemias on the first on-treatment measurement compared to admission (24.4% vs. 8.9%, P = 0.002). Conclusions: The proposed intravenous insulin protocol controls acute post-stroke hyperglycemia but frequently leads to hypokalemia. This issue needs to be addressed for the protocol to be suitable for use in larger, randomized controlled trial to explore its clinical effect.
引用
收藏
页码:443 / 451
页数:9
相关论文
共 50 条
  • [41] Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis
    Wahlgren, N.
    Thoren, M.
    Hojeberg, B.
    Kall, T. -B.
    Laska, A. -C.
    Sjostrand, C.
    Hoijer, J.
    Almqvist, H.
    Holmin, S.
    Lilja, A.
    Fredriksson, L.
    Lawrence, D.
    Eriksson, U.
    Ahmed, N.
    JOURNAL OF INTERNAL MEDICINE, 2017, 281 (03) : 273 - 283
  • [42] Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke
    Olavarria, Veronica V.
    LANCET NEUROLOGY, 2024, 23 (08) : 754 - 756
  • [43] Percutaneous vascular interventions versus intravenous thrombolytic treatment for acute ischaemic stroke
    Lindekleiv, Haakon
    Berge, Eivind
    Slot, Karsten M. H. Bruins
    Wardlaw, Joanna M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (10):
  • [44] Polypharmacy, functional outcome and treatment effect of intravenous alteplase for acute ischaemic stroke
    Jensen, M.
    Boutitie, F.
    Cheng, B.
    Cho, T. -H.
    Ebinger, M.
    Endres, M.
    Fiebach, J. B.
    Fiehler, J.
    Ford, I.
    Galinovic, I.
    Konigsberg, A.
    Puig, J.
    Roy, P.
    Wouters, A.
    Thijs, V.
    Lemmens, R.
    Muir, K. W.
    Nighoghossian, N.
    Pedraza, S.
    Simonsen, C. Z.
    Gerloff, C.
    Thomalla, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (02) : 532 - 539
  • [45] Reliability of point-of-care coagulometer measurements in patients with acute ischaemic stroke receiving intravenous fibrinolysis
    Guisado-Alonso, D.
    Fayos-Vidal, F.
    Marti-Fabregas, J.
    Prats-Sanchez, L.
    Marin-Bueno, R.
    Martinez-Domeno, A.
    Delgado-Mederos, R.
    Camps-Renom, P.
    NEUROLOGIA, 2020, 35 (03): : 155 - 159
  • [46] A retrospective study on intracerebral haemorrhage reduction by MRI versus CT in intravenous thrombolysis for acute ischaemic stroke
    Yun, Y. H.
    Chung, J. Y.
    Kang, M. J.
    Huh, J. T.
    Park, K. W.
    Cha, J. K.
    HONG KONG JOURNAL OF EMERGENCY MEDICINE, 2010, 17 (01) : 5 - 12
  • [47] Prognostic significance of age in patients with acute ischaemic stroke treated with intravenous thrombolysis
    Wnuk, Marcin
    Drabik, Leszek
    Derbisz, Justyna
    Slowik, Agnieszka
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2022, 56 (01) : 81 - 88
  • [48] Safety and Efficacy of Intravenous Alteplase for Acute Ischaemic Stroke in Patients With Prestroke Symptomaticity: An Analysis of the Virtual International Stroke Trials Archive
    Simon, Jenny
    Karlinski, Michal
    Niewada, Maciej
    VISTA-Acute Collaboration
    ACTA NEUROLOGICA SCANDINAVICA, 2025, 2025 (01):
  • [49] Effects of glycemic indicators on early neurological outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis
    Duan, Zuo-Wei
    Li, Zhi-Ning
    Zhai, Yu-Jia
    Liu, Teng-Fei
    Zhang, Cui-Cui
    Hu, Ting
    Wei, Xiu-E
    Rong, Liang-Qun
    Liu, Hai-Yan
    WORLD JOURNAL OF DIABETES, 2025, 16 (03)
  • [50] Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial
    Zhang, Xiao-Guang
    Zhu, Xiao-Qiong
    Xue, Jie
    Li, Zhi-Zhang
    Jiang, Hua-Yu
    Hu, Liang
    Yue, Yun-Hua
    BMJ OPEN, 2019, 9 (05):